BAX vs OMCL: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BAX is the larger of the two ($13.23B market cap): the incumbent the market prices for continued execution (12.50x forward earnings, beta 0.67). OMCL is the smaller challenger ($1.50B), actually pricier on forward earnings (16.23x): more room to run, but more to prove. If you believe OMCL earns its premium (16.23x forward earnings, so the market expects more from it), OMCL fits. If you believe in paying less for profit, BAX fits at 12.5x.

BAX vs OMCL: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBAXOMCLWhat it tells you
Market cap$13.23B$1.50BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E12.5016.23Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.670.89Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range69% of range4% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.031.14How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: BAX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how BAX and OMCL affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and OMCL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and OMCL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Baxter International (BAX) do?

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

What does Omnicell (OMCL) do?

Omnicell, Inc. (NASDAQ: OMCL) is a healthcare-technology company that builds medication-management and pharmacy-automation systems for hospitals, health systems, retail and specialty pharmacies, and other care settings. Its core products include automated dispensing cabinets (the XT and XR series), central-pharmacy robotics, IV compounding automation, and a growing layer of cloud software and services branded around what the company calls the Autonomous Pharmacy. Omnicell earns money from product sales (the hardware and installed systems) and from a rising base of recurring service and subscription revenue, including its Advanced Services and technician-enabled offerings, and it tracks annual recurring revenue (ARR) and product bookings as key operating metrics.

Full OMCL guide

BAX vs OMCL: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
  • OMCL drivers: Shift toward recurring software and services; Large installed base and replacement cycle.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For OMCL, omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy.

BAX or OMCL: which should you pick?

If the story you believe is BAX's (Margin and operational turnaround), BAX is the more direct way to own it; if it is OMCL's (Shift toward recurring software and services), OMCL is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and OMCL guides.

BAX vs OMCL: the full fundamentals

BAX. Baxter trades at about 12.5 times forward earnings and roughly 1.1 times sales, a modest valuation for medtech that reflects its low-growth profile and the debt load, even after a 31% rally in 2026. Reported GAAP profit is still negative over the trailing year because of special charges, so adjusted metrics carry most of the weight; consensus looks for about $0.60 of EPS in the fourth quarter and about $2.05 for 2027, roughly flat with the 2026 guidance range.

OMCL. Omnicell trades around $32.61 per share for a market capitalization near $1.5 billion as of November 20, 2026, about 1.2 times trailing sales and roughly 16 times forward earnings, with analysts' mean target near $57. The trailing GAAP P/E of about 34 is far above the forward multiple because GAAP earnings remain small, so the gap between GAAP and non-GAAP profitability is still central to how different investors value the name. Net cash of roughly $114 million and trailing free cash flow near $136 million give the balance sheet some cushion.

Headline figures (approximate, November 2026): BAX shows revenue (ttm) ~$11.6B, q3 2026 sales ~$2.98B, up ~5% year over year, q3 2026 adjusted eps ~$0.58 vs ~$0.52 expected (down ~16% YoY), 2026 adjusted eps guidance $2.05-2.15 (raised Oct 29, from $1.95-2.15); OMCL shows revenue (ttm) ~$1.24 billion (Q3 2026 down ~0.9% YoY), revenue (q3 2026) ~$308 million, non-gaap eps (q3 2026) ~$0.58 (vs ~$0.42 estimate), 2026 revenue guidance ~$1.225-1.231 billion.

The bottom line: BAX vs OMCL

BAX and OMCL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BAX and OMCL exposure against your real portfolio. It is not an investment adviser.

Wondering how BAX or OMCL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Baxter International

Ask Walnut's AI anything about BAX and see how it fits what you own.

FAQ

What is the difference between BAX and OMCL?

+

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. Omnicell, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BAX or OMCL the better stock?

+

Neither is universally better. BAX is the larger incumbent; OMCL is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BAX or OMCL?

+

On forward P/E (as of November 2026), BAX trades at 12.50x and OMCL at 16.23x, so BAX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BAX and OMCL?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BAX vs OMCL?

+

BAX: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.8 billion in total as of September 2026) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure, and the company still shows a GAAP net loss of roughly $619 million over the trailing twelve months. The FDA issued a warning letter dated September 29, 2026 citing manufacturing-practice violations at one US drug manufacturing site, and the end of transition-services fees from the kidney care sale in January 2027 removes a source of income. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. After a 31% rally this year, Wall Street's average rating is hold, and the average target of about $27.25 across 12 analysts sits only modestly above the share price. The turnaround is early and could take longer than management projects. OMCL: Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Coverage of the second-quarter report focused on a revenue beat paired with weaker EBITDA guidance, the third quarter showed a small year-over-year revenue decline, and consensus for the next two quarters implies EPS well below the first-half run rate, with 2027 EPS expected to fall about 19%, so the earnings trajectory may look uneven in the near term. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BAX or OMCL; figures are approximate and dated (as of November 2026). Verify current data before investing.